B. Jarocki

Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption.

G. Learn, M. Proschan, J. Hoxie, 2016, The New England journal of medicine.

Amdoxovir versus Placebo with Enfuvirtide plus Optimized Background Therapy for HIV-1-Infected Subjects Failing Current Therapy (Aactg A5118)

S. Hammer, D. Kuritzkes, J. Gerber, 2005, Antiviral therapy.

Dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA <500 000 copies/mL: week 48 outcomes from ACTG 5353

P. Sax, D. Haas, E. Acosta, 2019, The Journal of antimicrobial chemotherapy.

Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study.

J. Mellors, A. Collier, B. Taiwo, 2016, The lancet. HIV.

Minocycline treatment for HIV-associated cognitive impairment

D. Clifford, R. Ellis, M. Zink, 2011, Neurology.